Longevity.Technology UNLOCKED

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine GLP-1 off-ramps, ovarian aging, combination longevity therapies, AI-driven aging models, Alzheimer’s prevention, and regenerative stem cell advances.

• Fractyl Health released one-year data from its REVEAL-1 study, showing patients maintained roughly 78% of their GLP-1-related weight loss after receiving the Revita procedure. The results raise the possibility of a long-term off-ramp for Ozempic and similar drugs, though controlled trials are still needed.
• The Longevity Science Foundation launched a campaign to accelerate ovarian aging research, an area many experts consider critically underfunded despite its relevance to female healthspan and aging biology.
• Immorta Bio published peer-reviewed preclinical findings showing more than a 70% lifespan increase when senescent cell clearance was combined with regenerative therapies, supporting the idea that multiple aging mechanisms may need to be addressed simultaneously.
• Gero secured $17 million in new funding and expanded its collaboration with Chugai Pharmaceutical, applying physics-based models and large-scale human datasets to identify aging-related therapeutic targets.
• Eli Lilly signed a deal potentially worth more than $1 billion with AlzeCure Pharma to develop a preventive Alzheimer's therapy aimed at stopping disease processes years before symptoms emerge.
• MuseCell Innovations continues advancing stress-resistant stem cell therapies designed to repair damaged tissue while potentially opening new pathways for regenerative longevity medicine.

----------

News & References:

• A new off-ramp from Ozempic and Wegovy? → https://longevity.technology/news/a-new-off-ramp-from-ozempic-and-wegovy/
• Can crowdfunding change ovarian aging research (and opinions)? → https://longevity.technology/news/can-crowdfunding-change-ovarian-aging-research-and-opinions/
• Dual stem cell and anti-aging therapy extends mouse lifespan by over 70% → https://longevity.technology/news/dual-stem-cell-and-anti-aging-therapy-extends-mouse-lifespan-by-over-70/
• Gero raises $17m to model the mathematics of aging → https://longevity.technology/news/gero-raises-17m-to-model-the-mathematics-of-aging/
• Lilly places $1b bet on AlzeCure’s Alzheimer’s project → https://longevity.technology/news/lilly-places-1b-bet-on-alzecures-alzheimers-project/
• Harnessing Muse cells in longevity medicine → https://longevity.technology/news/harnessing-muse-cells-in-longevity-medicine/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: FlexBeam

FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.

Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.

Link: rechargehealthas.sjv.io/jRQyQ5

----------

Guests: Nir Barzilai

Director of the Institute for Aging Research at the Albert Einstein College of Medicine

LinkedIn: www.linkedin.com/in/nir-barzilai-7a86a7212/

Link to Nir's works:

einsteinmed.edu/faculty/484/nir-barzilai, www.sciencedirect.com/author/7005711408/nir-barzilai

----------

What if aging itself is the biggest medical opportunity of the 21st century?

Phil Newman and Dr. Nina Patrick sit down with Dr. Nir Barzilai, physician-scientist, professor of medicine and genetics, founding director of the Institute for Aging Research at Albert Einstein College of Medicine, and one of the pioneers of geroscience, to explore why targeting the biology of aging could delay multiple diseases at once.

Together they explain how decades of centenarian research revealed that healthy longevity is biologically achievable. From centenarians who remain healthy until their final year of life to real-world evidence showing GLP-1 therapies can reduce hospitalization and mortality, these insights are reshaping modern medicine. They also discuss metformin, SGLT2 inhibitors, biological age testing, longevity biomarkers, regulatory progress at the FDA, and the future of aging therapeutics.

Barzilai shares the scientific foundations behind the geroscience hypothesis, the idea that aging itself is the major driver of chronic disease. He explains why interventions that target aging biology may offer broader benefits than treating diseases one by one, and how decades of research have shifted the conversation from lifespan extension toward extending healthspan and compressing morbidity.

The discussion also explores the challenges facing the longevity field, from supplement overuse and biomarker validation to clinical trial design and regulatory pathways. Barzilai offers his perspective on emerging therapies, the promise of biological age measurement, and why the next generation of longevity medicine may look very different from today's healthcare model.

In this episode, you’ll learn:

• Why aging biology drives diseases like Alzheimer's, diabetes, and cardiovascular disease
• How centenarians compress morbidity and remain healthy into extreme old age
• Why GLP-1 therapies reduced hospitalization and death by roughly 60% in one study
• Why Barzilai tracks proteomics and believes biomarkers will transform longevity medicine
• Which longevity interventions he personally uses, including metformin and Rejuvant

If you want to understand how aging science is moving from theory to clinical reality, this episode connects cutting-edge research with practical insights for extending human healthspan.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine clinical AI, cortisol wearables, blood pressure monitoring, animal longevity biotech, stem cell therapies and next-generation obesity treatments.

• Longevitix launched a clinical intelligence platform designed for longevity, preventive and functional medicine clinics. The system combines laboratory results, wearable data, clinical notes and patient histories into physician-ready summaries, prioritized insights and personalized intervention plans.
• Rejuvenate Bio secured $6 million in new financing alongside a strategic collaboration with Merck Animal Health. The partnership aims to advance gene therapies for chronic and age-related conditions in pets, highlighting growing interest in animal longevity as a pathway for translational research.
• Adaptyx Biosciences presented data on a wearable cortisol sensor capable of continuously tracking free cortisol over multiple days. The device successfully captured daily cortisol rhythms and showed strong agreement with paired blood measurements.
• Celularity partnered with Fountain Life to offer placental-derived cell therapies at Fountain Life’s Florida facility. The collaboration leverages Florida’s evolving framework for early-stage stem cell treatments and could provide valuable real-world clinical data.
• South Korea became the first country to include Skylabs’ Cart BP Pro in its national hypertension treatment guidelines. The ring-shaped device continuously monitors blood pressure without the need for a traditional arm cuff, helping detect risks that often go unnoticed during routine clinic visits.
• MitoRx presented preclinical data for MTRX31, a mitochondrial-targeted obesity therapy designed to improve metabolic health through a mechanism distinct from GLP-1 drugs. The approach could serve as either a standalone treatment or a complementary therapy, making it a potentially attractive target for future pharmaceutical partnerships.

----------

News & References:

• Longevitix launches AI platform to tackle longevity data overload → https://longevity.technology/news/longevitix-launches-ai-platform-to-tackle-longevity-data-overload/
• Rejuvenate Bio secures funding and Merck partnership → https://longevity.technology/news/rejuvenate-bio-secures-funding-and-merck-partnership/
• Adaptyx debuts first continuous cortisol tracking wearable → https://longevity.technology/news/adaptyx-debuts-first-continuous-cortisol-tracking-wearable/
• Celularity, Fountain Life to offer experimental cell therapy in Florida → https://longevity.technology/news/celularity-fountain-life-to-offer-experimental-cell-therapy-in-florida/
• Goodbye, arm cuffs? South Korea bets on ring-type BP monitor → https://longevity.technology/news/goodbye-arm-cuffs-south-korea-bets-on-ring-type-bp-monitor/
• MitoRX’s new obesity drug targets metabolism, not appetite → https://longevity.technology/news/mitorxs-new-obesity-drug-targets-metabolism-not-appetite/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Acorn Biolabs

Acorn Biolabs is a science-driven regenerative medicine company that preserves your own hair follicle stem cells for future personalized treatments. Through a simple, non-invasive collection process, Acorn helps you bank your healthiest cells today, supporting regenerative skincare and hair therapies now while preparing for the future of longevity and cellular medicine.

Click the link below to learn more about Acorn's innovative approach to stem cell preservation.

Link: www.acorn.me

----------

Guests: Drew Taylor

CEO and co-founder of Acorn Biolabs

LinkedIn: https://www.linkedin.com/in/drew-taylor-65b6ab10/

Website: www.acorn.me

----------

What if the smartest longevity investment isn’t another supplement or infusion, but preserving your younger cells before aging changes them?

Phil Newman and Dr. Nina Patrick sit down with Drew Taylor, CEO and co-founder of Acorn Biolabs and biomedical engineer, to explore how regenerative medicine is shifting from reactive repair toward biological preservation and future optionality.

Together they explain why hair follicle stem cells may offer one of the most accessible entry points into autologous regenerative medicine. From collecting stem cells with simple hair plucking instead of invasive bone marrow extraction to cryopreserving younger biology for decades, Drew breaks down how Acorn’s platform aims to freeze cellular aging in time. The conversation also explores how these cells produce secretomes rich in growth factors, cytokines, collagen, extracellular vesicles, and exosomes that can later be used in skin rejuvenation, hair restoration, and orthopedic applications.

The discussion also dives into the darker side of the industry, including stem cell tourism, regulatory gaps, misinformation, and the risks patients face when traveling abroad for unverified treatments. Drew argues that ethical regenerative medicine must prioritize transparency, patient safety, and clinically validated protocols over hype.

They also explore the future of the field, including NK cells engineered from preserved hair follicle cells, cartilage regeneration research, AI-powered omics analysis, fertility applications, Parkinson’s research, and the possibility of one day growing replacement tissues and organs from your own preserved biology.

In this episode, you’ll learn:

• Why Acorn can generate up to 108 treatment vials from one collection
• How secretomes deliver growth factors, cytokines, collagen, and exosomes
• Why stem cell numbers decline faster than stem cell performance with age
• How NK cells derived from hair follicles suppressed cancer cell growth in lab studies
• Why Drew believes “cells will become the next currency in healthcare”

If you want to understand how regenerative medicine could shift from aesthetics to personalized disease prevention, this episode connects cutting-edge cell science with practical longevity strategies.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine wearable health innovation, brain-computer interfaces, physician-led longevity care, Alzheimer’s research, and the evolution of the longevity industry.

• ŌURA launched Ring 5, a redesigned device that is 40% smaller while maintaining week-long battery life. New features include blood pressure signals, breathing monitoring, GLP-1 insights, and integrated health data designed to make wearables a central health management platform.
• Ability Neurotech received approval in the Netherlands to begin long-term studies of its battery-free optical brain implant in ALS patients. The system is designed for everyday home use, highlighting the industry's shift from laboratory demonstrations toward real-world functionality.
• Elysium Health launched The Elysium Longevity Institute (TELI), combining physician oversight, advanced testing, supplements, prescriptions, and peptides. The move reflects a broader trend of established longevity brands expanding into comprehensive clinical care.
• A study of 69 women aged 65 and older linked poor sleep, increased Alzheimer’s genetic risk, greater tau accumulation, and weaker visual memory. Researchers suggest sleep and visual memory changes may offer valuable signals of early disease processes.
• From 95 startups across 32 countries entering the Longevity Show pitch competition to growing investment in diagnostics, prevention platforms, AI, and care delivery, the sector is increasingly focused on translating science into scalable healthspan solutions.
• The broader transition from sick care to prevention-led systems, where aging biology becomes a core risk factor and healthspan metrics replace disease counting. Insurance, pensions, and healthcare payment models need to adapt as longevity becomes embedded in economic infrastructure, not just products.

----------

News & References:

• What poor sleep may be telling women about Alzheimer’s? → https://longevity.technology/news/what-poor-sleep-may-be-telling-women-about-alzheimers/
• Five finalists advance in longevity pitch contest → https://longevity.technology/news/five-finalists-advance-in-longevity-pitch-contest/
• ŌURA’s smallest smart ring launched with expanded health monitoring → https://longevity.technology/news/ouras-smallest-smart-ring-launched-with-expanded-health-monitoring/
• Optical brain implant moves into real-world use → https://longevity.technology/news/optical-brain-implant-moves-into-real-world-use/
• Elysium expands into physician-led longevity care → https://longevity.technology/news/elysium-expands-into-physician-led-longevity-care/
• Public health faces longevity imperative → https://longevity.technology/news/public-health-faces-longevity-imperative/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: MuseCell Innovations

MuseCell Innovations is a science-backed regenerative medicine company developing patented Dezawa MuseCells®, unique stem cells that support the body's natural repair and regeneration processes. Benefits include cellular renewal, tissue repair, healthy aging, improved resilience, and overall wellbeing.

Click the link below to explore the science, research, and technology behind this innovative approach to regenerative medicine.

Link: musecellinnovations.com

----------

Guests:

Dominik Duscher MD PhD

President & Chief Executive Officer at MuseCell Innovations

Instagram: www.instagram.com/dr.dominikduscher/

Website: musecellinnovations.com

Dr. Jeffrey J. Wiegers

Chief Medical Officer at MuseCell Innovations

Instagram: www.instagram.com/jeffwiegers

Website: musecellinnovations.com

----------

What if a naturally occurring stem cell subpopulation could home to sites of injury and support tissue repair across multiple indications?

Phil Newman and Dr. Nina Patrick sit down with Dr. Dominik Duscher, MD PhD, President and CEO of MuseCell Innovations, and Dr. Jeffrey Wiegers, MD, Chief Medical Officer, to explore the unique properties of Dezawa MuseCells®. In this session, they describe these cells as highly enriched in a purified product with pluripotent-like potential, signaling that enables targeted homing, and immune tolerance that supports allogeneic use without major immune activation, based on early human experience.

From first-in-human intravenous use in acute myocardial infarction showing safety and encouraging left ventricle performance signals, to randomized placebo-controlled subacute ischemic stroke data showing higher response rates than placebo, they walk through human trial experience without overstating effects. They also discuss repeated intravenous dosing in an amyotrophic lateral sclerosis study suggesting stabilizing signal with minimal adverse events, single-arm spinal cord injury data, and early work in neonatal hypoxic-ischemic encephalopathy showing recovery signals in some infants.

They also address broader practicalities around manufacturing rigor, quality control, and provider competency as determinants of safety in clinical settings, and they describe the need for clear documentation and oversight to avoid unlicensed or inferior products.

In this episode, you’ll learn:

• Why pluripotency, homing ability, and immune tolerance are considered key features of Dezawa MuseCells® and how these properties may relate to tissue repair.
• What early human studies in conditions like heart attack, stroke, ALS, spinal cord injury, and neonatal brain injury have shown in terms of safety and early clinical signals.
• Why manufacturing quality, purification, and standardization are critical for consistency and safety in cell-based therapies.
• Why clinician expertise and proper oversight matter when these therapies move from research into clinical use.
• How to think about verifying product authenticity and avoiding unregulated or non-standard cell therapies.

If you want to understand the biological features, emerging human data, and practical considerations around Dezawa MuseCells® as discussed by leaders in the field, this episode connects cellular biology with real-world context for regenerative medicine and longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Nina Patrick examine FDA-cleared sleep diagnostics, safer CRISPR therapies, longevity clinic accountability, Retro Biosciences’ valuation, and AI-driven preventative healthcare.

• Sunrise received FDA clearance for Sunrise Air, a rechargeable at-home sleep apnea diagnostic using a chin sensor for multi-night testing. The device tracks airflow, oxygen, pulse, and snoring while targeting underdiagnosis linked to cardiovascular and cognitive decline.
• Insilico and Human Longevity have announced a multimillion-dollar collaboration to build what they describe as the industry’s first large-scale AI foundation model dedicated to longevity science. 
• Daewoong Pharmaceutical acquired Turn Biotechnologies’ partial reprogramming assets, including its ERA mRNA platform. The deal gives longevity-focused age reversal IP a new clinical and regulatory pathway.
• Scribe Therapeutics presented preclinical ELXR CRISPR data showing 18-month cholesterol reduction in primates through epigenetic PCSK9 silencing. The platform reduced off-target activity by up to 100-fold without permanently altering DNA.
• At the Milan Longevity Summit 2026 they explored how longevity clinics are moving from wellness branding toward evidence-based preventative medicine. Clinics are increasingly being pressured to prove outcomes through validated biomarkers and longitudinal patient data.
• Retro Biosciences reached a $1.8 billion valuation while advancing an Alzheimer’s drug into human trials. Retro’s approach focuses on boosting a natural cellular process called autophagy, essentially the body’s built-in recycling program.

----------

News & References:

• Retro Bio’s $1.8b moment: Hopes up as Alzheimer’s trial advances → https://longevity.technology/news/retro-bios-1-8b-moment-hopes-up-as-alzheimers-trial-advances/
• Longevity clinics face their proving ground → https://longevity.technology/news/longevity-clinics-face-their-proving-ground/
• Sunrise receives FDA clearance for rechargeable at-home sleep test → https://longevity.technology/news/sunrise-receives-fda-clearance-for-rechargeable-at-home-sleep-test/
• Daewoong acquires Turn Bio age-reversal assets → https://longevity.technology/news/daewoong-acquires-turn-bio-age-reversal-assets/
• Scribe Therapeutics debuts CRISPR platforms for cholesterol treatment → https://longevity.technology/news/scribe-therapeutics-debuts-crispr-platforms-for-cholesterol-treatment/
• Insilico and Human Longevity eye to predict disease early with AI → https://longevity.technology/news/insilico-and-human-longevity-eye-to-predict-disease-early-with-ai/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: fatty15.com/UNLOCKED

----------

Guests:

Jenny Duan

Co-Founder and CEO of Clair Health

LinkedIn: https://www.linkedin.com/in/jennysduan/

Website: https://wearclair.com/

Abhinav Agarwal

Co-Founder and CTO of Clair Health

LinkedIn: https://www.linkedin.com/in/agarwalaabhinav/

Website: https://wearclair.com/

----------

What if women’s hormones were tracked like heart rate, continuously and contextually, not through annual snapshots?

Phil Newman and Dr. Nina Patrick sit down with Jenny Duan, CEO of Clair, and Abhinav Argawal, CTO, to explore how a jewelry-inspired wrist wearable uses multi-sensor biosignals to infer estrogen and progesterone in real time across daily life.

They explain how signals such as skin temperature, HRV, sweat response, intracellular and extracellular current shifts, and more than 100 derived biomarkers are combined through sensor fusion to model hormone trajectories that update throughout the day. From forecasting an athlete’s rate of perceived exertion days before training to identifying progesterone patterns associated with PCOS and endometriosis risk, these examples show what continuous data reveals that snapshot testing cannot. The discussion also uncovers how this level of visibility allows the female cycle to be understood as nine distinct sub-phases rather than the traditional four.

They also discuss how lifestyle context, such as sleep, hydration, stress, and schedule, is integrated into the model to avoid contradictions between device feedback and lived experience. Early beta studies across PCOS, endometriosis, and perimenopause cohorts are already informing how this data can support fertility planning and symptom awareness.

In this episode, you’ll learn:

• Why the female cycle can be divided into nine hormone sub-phases
• How 230 biomarkers are refined into 100 inputs for hormone modeling
• How athletes can adjust hydration and nutrition before exertion spikes
• How progesterone trends may signal risk patterns for PCOS and endometriosis
• Why fertility and perimenopause represent 60% of early pre-orders

If you want to understand how continuous hormone visibility reshapes female health decisions across life stages, this episode connects biosensing, AI modeling, and practical insights for longevity.

Subscribe for weekly episodes that explore longevity science, preventative medicine, and the systems shaping how we live longer and better.

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: https://partners.fatty15.com/UNLOCKED

----------

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick examine pancreatic cancer immunotherapy, GLP-1 gene therapy, immune system rebuilding, cardiovascular plaque reversal and microbiome medicine.

• MatterBio filed its first IND application for Lm-LLO-TT, an engineered Listeria-based therapy targeting pancreatic ductal adenocarcinoma. Pending FDA clearance, the company plans a Phase 1/2a study evaluating safety, dosing and early efficacy in advanced pancreatic cancer patients resistant to conventional immunotherapy.
• Fractyl Health received European approval to begin a first-in-human Phase 1/2 trial of RJVA-001, GLP-1 gene therapy for obesity and type 2 diabetes. The therapy uses endoscopic ultrasound-guided pancreatic delivery to program beta cells to produce GLP-1 in response to meals rather than relying on repeated injections.
• Ossium Health presented clinical trial data showing successful engraftment using cryopreserved bone marrow collected from deceased organ donors. Researchers believe the banking platform could eventually simplify bone marrow transplantation logistics and expand future immune system renewal applications.
• Cyclarity shared new progress on therapies targeting 7-ketocholesterol, an oxidized cholesterol molecule linked to plaque instability and chronic arterial inflammation. Rather than slowing plaque growth, the company aims to physically remove toxic cholesterol deposits already embedded within blood vessel walls.
• Microbiotica reported positive Phase 1b MELODY-1 trial data for MB097, a microbiome therapy containing nine bacterial strains combined with KEYTRUDA in advanced melanoma patients. The therapy showed successful gut engraftment and encouraging signals that microbiome modulation may help overcome immunotherapy resistance.
• The episode also explored health equity in longevity medicine with Poonam Desai ahead of The Longevity Show. Discussions focused on sex-specific medicine, unequal access to longevity care and the risks of building precision health systems around biased clinical data.

----------

News & References:

• ‘Rebuilding the human immune system is possible’ → https://longevity.technology/news/rebuilding-the-human-immune-system-is-possible/
• Fractyl Health to begin EU trials for one-time weight loss gene therapy → https://longevity.technology/news/fractyl-health-to-begin-eu-trials-for-one-time-weight-loss-gene-therapy/
• Matter Bio takes pancreatic therapy to clinic → https://longevity.technology/news/matter-bio-takes-pancreatic-therapy-to-clinic/
• New data suggests plaque damage can be cleared → https://longevity.technology/news/new-data-suggests-plaque-damage-can-be-cleared/
• Microbiome medicine moves past wellness into clinics → https://longevity.technology/news/microbiome-medicine-moves-past-wellness-into-clinics/
• ‘Equity in longevity is the entire ballgame’ → https://longevity.technology/news/equity-in-longevity-is-the-entire-ballgame/

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn

----------

Sponsor: Fatty15

Fatty15 is a science-backed, patented, award-winning supplement with pure C15:0 that strengthens cell membranes and supports healthy aging at the cellular level. Benefits include deeper sleep, calmer mood, improved energy, and overall wellbeing.

Click the link below to learn more and use code UNLOCKED for 15% off the 90-day Starter Kit.

Link: fatty15.com/UNLOCKED

----------

Guests: Valter Longo

Professor and Director at USC Longevity Institute

Instagram: https://www.instagram.com/prof_valterlongo/

Website: https://valterlongo.com/

----------

What if a five-day diet could reset metabolism, regenerate tissue, and challenge decades of nutrition dogma?

Phil Newman and Dr. Nina Patrick sit down with Valter Longo, USC Longevity Institute researcher and architect of the fasting mimicking diet, to explore how short, periodic fasting cycles may interact with aging biology, insulin signaling, and tissue regeneration.

Together they break down how the fasting mimicking diet differs from water fasting and simple calorie restriction, and why its plant based, low protein, low sugar, and high fat composition is designed to maintain protection while still triggering nutrient sensing pathways. Longo explains how in clinical and preclinical data, repeated cycles have shown improvements in insulin resistance, reductions in diabetes medication use by 60 to 70% in some cohorts, and measurable shifts in metabolic biomarkers compared to Mediterranean diet controls.

The conversation also explores mechanistic findings, including autophagy activation peaking around day five in human studies, stem cell associated regeneration signals, and embryonic like gene expression patterns observed in multiple organ systems. In animal models, these cycles have been associated with pancreatic regeneration, kidney repair after induced damage, and normalization of cholesterol and glucose regulation.

In this episode, you’ll learn:

• Autophagy activation and peak biological signaling observed around day five in human fasting mimicking protocols
• Clinical trials in diabetes showing 60 to 70% reduction in medication use within one year in some populations
• Animal studies showing reversal of severe metabolic dysfunction with monthly fasting mimicking cycles
• Protein restriction and mTOR IGF-1 signaling pathways repeatedly linked with lifespan extension across multiple species
• Risk discussion around prolonged fasting triggering energy conserving metabolic adaptation states

If you want to understand how structured fasting protocols may interact with aging pathways, metabolic disease, and regenerative biology, this episode connects clinical evidence with evolutionary and mechanistic frameworks shaping modern longevity science.

Subscribe for weekly episodes exploring longevity science, preventative medicine, and the systems shaping human healthspan.